Our Featured Experts

Bruce D. Cheson, MD
Dr. Bruce D. Cheson on Obinutuzumab/ Bendamustine Survival Benefit in iNHL
Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Deputy Chief, Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, discusses the phase III GADOLIN study, which looks at the anti-CD20 agent obinutuzumab (Gazyva) and bendamustine compared with bendamustine alone in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).
Matthew J. Ellis, MD, PhD
Oncology Specialists
Publication Bottom Border
Border Publication